Titre :

FOLFIRINOX De-Escalationin Advanced Pancreatic Cancer: A MulticenterReal-LifeStudy

Auteur(s) :

Chevalier, Hortense [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Vienot, Angélique [Auteur]
Cooperator Multidisciplinary Oncology Group [GERCOR]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Lièvre, Astrid [Auteur]
Chemistry, Oncogenesis, Stress and Signaling [COSS]
Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou]
Edeline, Julien [Auteur]
CRLCC Eugène Marquis [CRLCC]
Nutrition, Métabolismes et Cancer [NuMeCan]
El Hajbi, Farid [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Peugniez, Charlotte [Auteur]
Hôpital Saint Vincent de Paul de Lille
Vernerey, Dewi [Auteur]
Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) [CEF2P / CARCINO]
Cooperator Multidisciplinary Oncology Group [GERCOR]
Meurisse, Aurélia [Auteur]
Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) [CEF2P / CARCINO]
Hammel, Pascal [Auteur]
Université Paris Diderot - Paris 7 [UPD7]
Hôpital Beaujon [AP-HP]
Cooperator Multidisciplinary Oncology Group [GERCOR]
Neuzillet, Cindy [Auteur]
Université de Versailles Saint-Quentin-en-Yvelines [UVSQ]
Institut Curie [Paris]
Cooperator Multidisciplinary Oncology Group [GERCOR]
Borg, Christophe [Auteur]
Centre Hospitalier Régional Universitaire de Besançon [CHRU Besançon]
Cooperator Multidisciplinary Oncology Group [GERCOR]
Turpin, Anthony [Auteur correspondant]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Cooperator Multidisciplinary Oncology Group [GERCOR]

Titre de la revue :

Oncologist

Pagination :

e1701-e1710

Éditeur :

Oxford University Press

Date de publication :

2020-11-01

ISSN :

1083-7159

Mot(s)-clé(s) en anglais :

FOLFIRINOX
Maintenance treatment
Advanced pancreatic cancer
Real-life study
Quality of life

Discipline(s) HAL :

Sciences du Vivant [q-bio]
Sciences du Vivant [q-bio]/Cancer
Sciences du Vivant [q-bio]/Médecine humaine et pathologie/Hépatologie et Gastroentérologie

Résumé en anglais : [en]

Background - Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil [5FU], folinic acid, irinotecan, and oxaliplatin) induction chemotherapy (CT) followed by de-escalation as a maintenance ...
Lire la suite >Background - Our study describes the feasibility and efficacy of a first-line FOLFIRINOX (5-fluorouracil [5FU], folinic acid, irinotecan, and oxaliplatin) induction chemotherapy (CT) followed by de-escalation as a maintenance strategy for advanced pancreatic cancer. Materials and methods - This multicenter retrospective study was conducted from January 2011 to December 2018. FOLFIRINOX de-escalation was defined as stopping oxaliplatin and/or irinotecan after at least four cycles of FOLFIRINOX, without evidence of disease progression. Maintenance schedules were fluoropyrimidine monotherapy (intravenous or oral [capecitabine]), FOLFOX (5FU, oxaliplatin), or FOLFIRI (5FU, irinotecan). Primary endpoint was overall survival (OS). Secondary endpoints were first progression-free survival (PFS1), second progression-free survival (PFS2), and toxicity. Results - Among 321 patients treated with FOLFIRINOX, 147 (45.8%) were included. Median OS was 16.1 months (95% confidence interval [CI], 13.7-20.3) and median PFS1 was 9.4 months (95% CI, 8.5-10.4). The preferred maintenance regimen was FOLFIRI in 66 (45%) patients versus 5FU monotherapy in 52 (35%) and FOLFOX in 25 (17%) patients. Among 118 patients who received maintenance CT with FOLFIRI or 5FU, there was no difference in PFS1 (median, 9.0 vs. 10.1 months, respectively; p = .33) or OS (median, 16.6 vs. 18.7 months; p = .86) between the two maintenance regimens. Reintroduction of FOLFIRINOX was performed in 20.2% of patients, with a median PFS2 of 2.8 months (95% CI, 2.0-22.3). The rates of grade 3-4 toxicity were significantly higher with FOLFIRI maintenance CT than with 5FU (41% vs. 22%; p = .03), especially for neuropathy (73% vs. 9%). Conclusion - 5FU monotherapy maintenance appeared to be as effective as FOLFIRI, in a FOLFIRINOX de-escalation strategy, which is largely used in France. Implications for practice - FOLFIRINOX de-escalation and maintenance is a feasible strategy in advanced pancreatic cancer that decreases chemotherapy toxicity to improve both survival and quality of life. Survivals in patients with maintenance therapy are clinically meaningful. Fluoropyrimidine monotherapy maintenance seems to be as efficient as FOLFIRI and should be a reference arm in future pancreatic cancer maintenance trials.Lire moins >

Langue :

Anglais

Vulgarisation :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277
• Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017

Date de dépôt :

2024-02-17T04:28:33Z